|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
25
|
|
pubmed:dateCreated |
2011-8-31
|
|
pubmed:abstractText |
To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin (SCCS).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AdamskiHenriH,
pubmed-author:AvrilMarie-FrançoiseMF,
pubmed-author:Basset-SeguinNicoleN,
pubmed-author:BuffardValérieV,
pubmed-author:CertainAgnèsA,
pubmed-author:CrickxBéatriceB,
pubmed-author:DompmartinAnneA,
pubmed-author:Duval-ModesteAnne-BénédicteAB,
pubmed-author:DuvalXavierX,
pubmed-author:DuvillardPierreP,
pubmed-author:FaivreSandrineS,
pubmed-author:GellyJulienJ,
pubmed-author:GrangeFlorentF,
pubmed-author:LacroixLudovicL,
pubmed-author:MansardSandrineS,
pubmed-author:MaubecEveE,
pubmed-author:MentréFranceF,
pubmed-author:PetrowPeterP,
pubmed-author:SaezPierreP,
pubmed-author:Scheer-SenyarichIsabelleI
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3419-26
|
|
pubmed:meshHeading |
pubmed-meshheading:21810686-Adult,
pubmed-meshheading:21810686-Aged,
pubmed-meshheading:21810686-Aged, 80 and over,
pubmed-meshheading:21810686-Antibodies, Monoclonal,
pubmed-meshheading:21810686-Antineoplastic Agents,
pubmed-meshheading:21810686-Carcinoma, Squamous Cell,
pubmed-meshheading:21810686-Female,
pubmed-meshheading:21810686-Follow-Up Studies,
pubmed-meshheading:21810686-Humans,
pubmed-meshheading:21810686-Lymphatic Metastasis,
pubmed-meshheading:21810686-Male,
pubmed-meshheading:21810686-Middle Aged,
pubmed-meshheading:21810686-Skin Neoplasms,
pubmed-meshheading:21810686-Survival Rate,
pubmed-meshheading:21810686-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
|
|
pubmed:affiliation |
Hôpital Bichat, Service de Dermatologie, 46 rue Henri Huchard, Paris, cedex 75877, France. eve.maubec@bch.aphp.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
